Literature DB >> 26898994

Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

P Khare1, A K Jaiswal1, C D P Tripathi1, S Sundar2, A Dube1.   

Abstract

It is well known that a patient in clinical remission of visceral leishmaniasis (VL) remains immune to reinfection, which provides a rationale for the feasibility of a vaccine against this deadly disease. In earlier studies, observation of significant cellular responses in treated Leishmania patients as well as in hamsters against leishmanial antigens from different fractions led to its further proteomic characterization, wherein S-adenosyl-L-homocysteine hydrolase (AdoHcy) was identified as a helper type 1 (Th1) stimulatory protein. The present study includes immunological characterization of this protein, its cellular responses [lymphoproliferation, nitric oxide (NO) production and cytokine responses] in treated Leishmania-infected hamsters and patients as well as prophylactic efficacy against Leishmania challenge in hamsters and the immune responses generated thereof. Significantly higher cellular responses were noticed against recombinant L. donovani S-adenosyl-L-homocysteine hydrolase (rLdAdoHcy) compared to soluble L. donovani antigen in treated samples. Moreover, stimulation of peripheral blood mononuclear cells with rLdAdoHcy up-regulated the levels of interferon (IFN)-γ, interleukin (IL)-12 and down-regulated IL-10. Furthermore, vaccination with rLdAdoHcy generated perceptible delayed-type hypersensitivity response and exerted considerably good prophylactic efficacy (∼70% inhibition) against L. donovani challenge. The efficacy was confirmed by the increased expression levels of inducible NO synthase and Th1-type cytokines, IFN-γ and IL-12 and down-regulation of IL-4, IL-10 and transforming growth factor (TGF)-β. The results indicate the potentiality of rLdAdoHcy protein as a suitable vaccine candidate against VL.
© 2016 British Society for Immunology.

Entities:  

Keywords:  cellular immune response prophylactic efficacy; rLdAdoHcy; treated Leishmania infected hamsters and patients

Mesh:

Substances:

Year:  2016        PMID: 26898994      PMCID: PMC4954996          DOI: 10.1111/cei.12780

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  55 in total

1.  Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.

Authors:  Pramod K Kushawaha; Reema Gupta; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

2.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

Authors:  R X Armijos; M M Weigel; M Calvopina; A Hidalgo; W Cevallos; J Correa
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

3.  Specific inhibitory effect of 3-deazaneplanocin A against several Leishmania mexicana and L. braziliensis strains.

Authors:  J L Avila; A Avila; M A Polegre; V E Marquez
Journal:  Am J Trop Med Hyg       Date:  1997-10       Impact factor: 2.345

Review 4.  Development of vaccines against leishmaniasis.

Authors:  F Modabber
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure.

Authors:  A Hailu; J N Menon; N Berhe; L Gedamu; T H Hassard; P A Kager; J Olobo; P A Bretscher
Journal:  J Infect Dis       Date:  2001-05-31       Impact factor: 5.226

Review 6.  Cytokine-producing T cell subsets in human leishmaniasis.

Authors:  K Kemp
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

7.  Sibling species in the Llutzomyia longipalpis complex differ in levels of mRNA expression for the salivary peptide, maxadilan.

Authors:  H Yin; D E Norris; G C Lanzaro
Journal:  Insect Mol Biol       Date:  2000-06       Impact factor: 3.585

8.  Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Shyam Sundar; Sudhir Sinha; Anuradha Dube
Journal:  Vaccine       Date:  2008-07-24       Impact factor: 3.641

9.  From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Authors:  Rhea N Coler; Malcolm S Duthie; Kimberly A Hofmeyer; Jeffery Guderian; Lakshmi Jayashankar; Julie Vergara; Tom Rolf; Ayesha Misquith; John D Laurance; Vanitha S Raman; H Remy Bailor; Natasha Dubois Cauwelaert; Steven J Reed; Aarthy Vallur; Michelle Favila; Mark T Orr; Jill Ashman; Prakash Ghosh; Dinesh Mondal; Steven G Reed
Journal:  Clin Transl Immunology       Date:  2015-04-10

10.  Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.

Authors:  Pramod K Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Prashant Khare; Anil Kumar Jaiswal; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more
  1 in total

Review 1.  Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates.

Authors:  Surbhi Jain; Utkarsha Sahu; Awanish Kumar; Prashant Khare
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.